MedTrace Logo

Angiotensin II Blockade for Chronic Allograft Nephropathy

NCT00067990 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 153

Last updated 2017-09-18

Study results available
· View outcomes & findings →

Summary

Chronic allograft nephropathy continues to be a major cause of kidney transplant loss and return to dialysis. Treatment options are limited and the course of the disease tends to be progressive. This trial is designed to prevent a major mediator of this process, namely the expansion of the cortical interstitial compartment of the kidney where most of the scarring occurs. The drug being studied, Losartan, has proven efficacious in a number of kidney diseases.

Conditions

Interventions

DRUG

Losartan 100mg

To be started within three months of transplant and continued for five years.

DRUG

Placebo

No treatment with continued follow-up for five years.

Sponsors & Collaborators

Principal Investigators

  • Hassan N. Ibrahim, M.D., M.S. · University of Minnesota

  • Bertram Kasiske, M.D. · Hennepin County Medical Center, Minneapolis

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-12-31
Primary Completion
2011-06-30
Completion
2011-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00067990 on ClinicalTrials.gov